

GenCore version 5.1.4 p5-4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: May 7, 2003, 10:28:59 : Search time 35 seconds
(without alignments)
571.074 Million cell updates/sec

Title: US-10-039-659-4
Perfect score: 796
Sequence: 1 MNMLLACLVAGFCAGAAVA.....NTSSSKRNKRLISANSGL 150

Scoring table:
Gapop 10.0, Capex 0.0

Searched: 908470 seqs, 13325620 residues
Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: A_Genoseq 101002:*

1: /SID22/qcqdala/geneseq/geneseq-emb1/AA1960.DAT*

2: /SID22/qcqdala/geneseq/geneseq-emb1/AA1961.DAT*

3: /SID22/qcqdala/geneseq/geneseq-emb1/AA1962.DAT*

4: /SID22/qcqdala/geneseq/geneseq-emb1/AA1963.DAT*

5: /SID22/qcqdala/geneseq/geneseq-emb1/AA1964.DAT*

6: /SID22/qcqdala/geneseq/geneseq-emb1/AA1965.DAT*

7: /SID22/qcqdala/geneseq/geneseq-emb1/AA1966.DAT*

8: /SID22/qcqdala/geneseq/geneseq-emb1/AA1967.DAT*

9: /SID22/qcqdala/geneseq/geneseq-emb1/AA1968.DAT*

10: /SID22/qcqdala/geneseq/geneseq-emb1/AA1969.DAT*

11: /SID22/qcqdala/geneseq/geneseq-emb1/AA1970.DAT*

12: /SID22/qcqdala/geneseq/geneseq-emb1/AA1971.DAT*

13: /SID22/qcqdala/geneseq/geneseq-emb1/AA1972.DAT*

14: /SID22/qcqdala/geneseq/geneseq-emb1/AA1973.DAT*

15: /SID22/qcqdala/geneseq/geneseq-emb1/AA1974.DAT*

16: /SID22/qcqdala/geneseq/geneseq-emb1/AA1975.DAT*

17: /SID22/qcqdala/geneseq/geneseq-emb1/AA1976.DAT*

18: /SID22/qcqdala/geneseq/geneseq-emb1/AA1977.DAT*

19: /SID22/qcqdala/geneseq/geneseq-emb1/AA1978.DAT*

20: /SID22/qcqdala/geneseq/geneseq-emb1/AA1979.DAT*

21: /SID22/qcqdala/geneseq/geneseq-emb1/AA1980.DAT*

22: /SID22/qcqdala/geneseq/geneseq-emb1/AA1981.DAT*

23: /SID22/qcqdala/geneseq/geneseq-emb1/AA1982.DAT*

SUMMARIES

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	ID	Description
1	796	100.0	150	AA044397	Human thymus expe
2	790	99.2	150	AA019607	Human thymus expe
3	782	98.2	150	AA030565	Human chemokine ZS
4	777	97.5	150	AA021844	Human signal pep1
5	775.5	97.4	149	AA041938	Human chemokine bc
6	775.5	97.4	149	AA041161	Human chemokine bc
7	775.5	97.4	149	AA019608	Human thymus expe
8	775.5	97.4	149	AA019608	Human chemokine bc
9	668	83.9	127	AA020024	Human chemokine TE
10	668	83.9	127	AA07731	Human chemokine TE

11	668	83.9	127	AA014157	Human TECK protein
12	316	39.7	144	AA044396	Mouse thymus expe
13	224	28.1	121	AA077312	Murine chemokine T
14	127	16.0	284	AA099211	Murine SLC-interle
15	117.5	14.8	132	AA01435	Murine secondary 1
16	117.5	14.8	133	AA094209	Murine SLC-2 m
17	115	14.4	133	AA028511	Product of clone L
18	115	14.4	133	AA050884	Amino acid sequence
19	114	14.3	94	AA077141	Human SLYA26 var1a
20	112	14.1	93	AA07271	Novel beta chemok
21	112	14.1	94	AA06445	Human eosinophil c
22	112	14.1	94	AA082716	Human type CC chem
23	112	14.1	94	AA082716	Human zchemo-8 pr
24	112	14.1	94	AA082716	Human ER222 poly
25	112	14.1	94	AA082716	Human ER222 poly
26	112	14.1	94	AA082716	Human ER222 poly
27	107	13.4	122	AA025941	Human ER222 poly
28	107	13.4	122	AA025941	Human ER222 poly
29	105.5	13.3	147	AA025941	Human ER222 poly
30	105.5	13.3	147	AA025941	Human ER222 poly
31	104.5	13.0	111	AA020021	Human ER222 poly
32	103.5	13.0	111	AA020021	Human ER222 poly
33	103.5	13.0	111	AA020021	Human ER222 poly
34	103.5	13.0	129	AA014154	Human ER222 poly
35	103.5	13.0	129	AA014154	Human ER222 poly
36	103.5	13.0	134	AA014154	Human ER222 poly
37	103.5	13.0	134	AA014154	Human ER222 poly
38	103.5	13.0	134	AA014154	Human ER222 poly
39	103.5	13.0	134	AA014154	Human ER222 poly
40	103.5	13.0	134	AA014154	Human ER222 poly
41	103.5	13.0	134	AA014154	Human ER222 poly
42	103.5	13.0	134	AA014154	Human ER222 poly
43	103.5	13.0	134	AA014154	Human ER222 poly
44	103.5	13.0	134	AA014154	Human ER222 poly
45	103.5	13.0	134	AA014154	Human ER222 poly

ALIGNMENTS

RESULT 1
ID AA044397 standard; Protein: 150 AA.

AA044397: (first entry)

DE Human thymus expressed chemokine.

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

FW Human thymus expressed chemokine; TECK; MIP-3alpha; MIP-2beta;

PN W09844117-A1.
 XX 08-OCT-1998.
 XX 27-MAR-1998: 98W0-INS06115.
 XX 09-MAY-1997: 97US-0046083.
 XX 28-MAR-1997: 97US-0042852.
 XX (SINO) CYMOSINTECH INC.
 XX
 XX Shepherd PO.
 XX
 XX WPI: 1998-557114/47.
 XX N-PSDB: AAV45444.
 XX
 XX Key human chemokine ESTs are used for a protein inflammatory
 PT disease, lymphocyte migration and ischemia/reperfusion injury
 PS
 XX Claim 1: Page 80-81; 105pp; English.
 CC
 CC This is the amino acid sequence of a novel human chemokine,
 CC designated 2S1G-35, that has homology to members of the
 CC beta-chemokine family, in particular to murine macrophage
 CC inflammatory protein (2S1G-35 protein). It includes a 4-Cys
 CC motif (residues 36, 37, 58 and 75) that is characteristic of
 CC beta-chemokines. The invention provides 2S1G-35 polypeptides
 CC and polynucleotides, an expression vector, a cultured cell carrying
 CC the vector, a method of producing the protein, a specific antibody,
 CC a binding protein, and a pharmaceutical composition comprising for
 CC the regulation of acute and chronic inflammatory disease conditions,
 CC lymphocyte migration and ischemia/reperfusion injury.
 XX
 XX Sequence 150 AA.
 SQ
 Query Match 98.2% Score 783. DB 19: Length 150;
 Best local Similarity 98.7% Pred No 20-85;
 Matches 149; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1 MNLMLACLVAGFLGMAPAVHTGGVFFEDCLAHYPTQWAVLPAMTYPIQVNSGSL 60
 DB 1 MNLMLACLVAGFLGMAPAVHTGGVFFEDCLAHYPTQWAVLPAMTYPIQVNSGSL 60
 QY 61 FAALTYLFFHFVCGTRVFVGFAMTTPANRYPAKIHNNMVFQAGHVAKKLSG 120
 DB 61 FAALTYLFFHFVCGTRVFVGFAMTTPANRYPAKIHNNMVFQAGHVAKKLSG 120
 QY 121 NSKLSSEKFNPTSSSRNVSLLISANSGL 150
 DB 121 NSKLSSEKFNPTSSSRNVSLLISANSGL 150
 RESULT 4
 AAV21844 standard; Protein: 150 AA.
 XX
 XX AAV21844.
 XX
 XX 20-SEP-1999 (first entry)
 XX
 XX Human signal peptide containing protein (SICP) (clone ID 1634813).
 XX
 XX Signal peptide containing protein (SICP); human; cancer; immune response;
 XX adenocarcinoma; leukemia; lymphoma; melanoma; myeloma; sarcoma; AIDS;
 XX Addison's disease; adult respiratory distress syndrome; allergy; anemia;
 XX asthma; atherosclerosis; bronchitis; cholecystitis; Crohn's disease;
 XX ulcerative colitis; atopic dermatitis; dermatomyositis; emphysema;
 XX diabetes mellitus; atrophic gastritis; glomerulonephritis; gout; trauma;
 XX Graves' disease; hypereosinophilia; irritable bowel syndrome; infection;
 XX lupus erythematosus; multiple sclerosis; psoriasis; polyarthritis; inflammation;
 XX osteoarthritis; osteoporosis; pancreatitis; polymyositis; scleroderma;

XX
 XX rheumatoid arthritis; Sjogren's syndrome; autoimmune thyroiditis.
 XX Homo sapiens.
 XX W09933981-A2.
 XX 08-JUL-1999.
 XX 42-JAN-1998: 98W0-0027598.
 XX 31-JAN-1997: 97US-0002485.
 XX (INCYTE) INCYTE PHARM INC.
 XX
 XX Hargim MS, Corley NG, Cuelper KJ, Hillman JL, Lal P;
 XX Sather SK, Shah P;
 XX WPI: 1998-410444/39.
 XX N-PSDB: AAV22078.
 XX
 XX Human signal-peptide containing protein coding sequences used to
 PT treat cancer and immune responses
 PS
 XX Claim 1: Page 78-79; 99pp; English.
 CC The invention provides human signal peptide containing proteins (SICP)
 CC (AAV21841-85) and polynucleotides (AAV21876-90) encoding the proteins.
 CC A host cell containing a vector comprising SICP DNA can be used, in conjunction
 CC with a pharmaceutical carrier, to treat or prevent a cancer or an
 CC immune response. The cancers that can be treated or prevented include
 CC leukemia, adenocarcinoma, lymphoma, melanoma, myeloma, sarcoma,
 CC bone, bone marrow, brain, breast, cervix, gall bladder, ovary,
 CC gastrointestinal tract, heart, kidney, liver, lung, muscle, pancreas,
 CC prostate, parathyroid, penis, rectum, skin, skin glands, skin, spleen,
 CC testis, thymus, thyroid, and uterus. Addison's disease, adult respiratory
 CC distress syndrome, allergies, anemia, asthma, atherosclerosis, atopic
 CC bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic
 CC dermatitis, dermatomyositis, diabetes mellitus, emphysema, atrophic
 CC gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia,
 CC irritable bowel syndrome, lupus erythematosus, multiple sclerosis,
 CC myasthenia gravis, myeloma, osteoarthritis, osteoporosis, pancreatitis,
 CC polyarthritis, polymyositis, psoriasis, rheumatoid arthritis, scleroderma,
 CC Sjogren's syndrome, and autoimmune thyroiditis, complications of cancer,
 CC infections, and trauma.
 XX
 XX Sequence 150 AA:
 SQ
 Query Match 97.6% Score 777; DB 20: Length 150;
 Best local Similarity 98.0% Pred No 20-85;
 Matches 147; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1 MNLMLACLVAGFLGMAPAVHTGGVFFEDCLAHYPTQWAVLPAMTYPIQVNSGSL 60
 DB 1 MNLMLACLVAGFLGMAPAVHTGGVFFEDCLAHYPTQWAVLPAMTYPIQVNSGSL 60
 QY 61 FAALTYLFFHFVCGTRVFVGFAMTTPANRYPAKIHNNMVFQAGHVAKKLSG 120
 DB 61 FAALTYLFFHFVCGTRVFVGFAMTTPANRYPAKIHNNMVFQAGHVAKKLSG 120
 QY 121 NSKLSSEKFNPTSSSRNVSLLISANSGL 150
 DB 121 NSKLSSEKFNPTSSSRNVSLLISANSGL 150
 RESULT 5
 AAV41938 standard; Protein: 149 AA.
 XX
 XX AAV41938.
 XX
 XX AAV41938.

XX DE Human thymus expressed chemokine (PCK variant).

XX KW Thymus expressed chemokine (PCK variant).

XX KW Leukemia; lymphoma; carcinoma; chronic disease; colitis; inflammation; therapy; diagnosis; variant.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT Misc-difference 104 /note="encoded by AYC"

XX FT W0200053635-A1.

XX PD 14-SEP-2000.

XX PF 10-MAR-2000; 2000W-10506240

XX PP 11-MAR-1999; 99US-0272162.

XX PA (LEUK-) LEUKOSITE INC.

XX P1 Andrew DP, Zabel BA, Ponath PD;

XX DR WP1: 2000-572263/53.

XX DR N-PSDR: AAA88566.

XX PT Antibody or its antigen-binding fragment which binds to the mammalian

XX PT CC chemokine receptor GPR-96, useful for treating inflammatory

XX PT diseases, cancer or inhibiting GPR-96 mediated homing of leukocytes to

XX PT mucosal tissue.

XX PS Disclosure: Fig 23; 14pp; English.

XX CC This sequence represents a variant of human thymus expressed

XX CC chemokine TECK. It lacks the Ala 139 residue of TECK (see AAB19697).

XX CC The invention relates to an antibody that binds to the chemokine

XX CC receptor GPR-96 (see AAB13555) and blocks the binding of a ligand,

XX CC especially TECK, to the receptor. Also provided is a method of

XX CC identifying agents which can bind to GPR-96 and inhibit the

XX CC binding of a ligand and/or modulate a function of GPR-96. The

XX CC antibodies can be used to detect TECK. They are useful for

XX CC treating an inflammatory disease, cancer and inhibiting

XX CC GPR-96 mediated homing of leukocytes to mucosal tissue. The

XX CC cancer treated is acute or chronic leukemia (e.g., acute T cell

XX CC lymphoblastic leukaemia, acute B-cell lymphoblastic leukaemia,

XX CC chronic T-cell lymphoblastic leukaemia, chronic B-cell lymphoblastic

XX CC leukaemia), lymphoma (e.g., Hodgkin's disease, T cell lymphoma) or

XX CC carcinoma (e.g., breast, melanoma, myeloma, or adenoma). The

XX CC inflammatory diseases treated are Crohn's disease, colitis,

XX CC (claimed), inflammatory bowel disease, mastitis, vaginitis,

XX CC cholangitis or pericholangitis, chronic bronchitis, asthma, graft

XX CC versus host disease, hypersensitivity pneumonitis, eczema,

XX CC diseases, sarcoidosis, and other idiopathic conditions. Other

XX CC diseases that can be treated by the antibodies are autoimmune

XX CC diseases (e.g., rheumatoid arthritis, multiple sclerosis), infectious

XX CC diseases (e.g., bacterial and viral infections), atherosclerosis,

XX CC resenosis, AIDS, pancreatitis, insulin-dependent diabetes mellitus,

XX CC and diseases in which angiogenesis or neovascularization play a role.

XX SO Sequence 149 AA:

Query Match 97.48, Score 775.5, DB 21, Length 149

Best Local Similarity 98.78; Pred. No. 1,8e-85;

Matches 148; Conservative: 0; Mismatches 1, Indels 1, Gaps 1,

07 1 MNWLGLACVAGHLSMAVAHVGVEFPCCLAVHPLGMVAPRWYRIQVSGSNTL 60

DB 1 MNWLGLACVAGHLSMAVAHVGVEFPCCLAVHPLGMVAPRWYRIQVSGSNTL 60

07 61 FAATFLKRRKRVCONKSLVWCAHLLZAFRVYARLRHDMQTFQATTAHVPR 126

DE 61 FAATFLKRRKRVCONKSLVWCAHLLZAFRVYARLRHDMQTFQATTAHVPR 126

07 121 NSEISSKFSKFSNFISSSKFNANSLISANSNL 150

DB 120 KAFIISKFNFISSSKFNANSLISANSNL 149

RESULT 8

AAE19792

ID AAE19792 standard; Protein: 149 AA.

XX AC AAE19792;

XX DT 18-JUN-2002 (first entry)

XX DE Human chemokine beta-15 (CKbeta-15).

XX KW Human chemokine CC protein; chemokine beta 15; CKbeta 15; thymus;

XX KW therapy; interleukin-8; T-lymphocyte; bone progenitor cell;

XX KW apoptosis; leukemia; chromosome identification; cytostatic.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT Peptide 1..20

XX FT /label= Signal_peptide

XX FT Protein 21..149

XX FT /note="Human mature CKbeta 15"

XX PY HG007910a3-A1.

XX PD 14-FEB-2002.

XX PF 19-MAR-1999; 99US-0272162.

XX PP 17-JUN-1996; 96US-019837P.

XX PP 15-JUN-1997; 97US-0874460.

XX PA (WEIV) WEI Y.

XX PA (KPEI) KPEIDP B L.

XX PA (POSEF) POSEN C A.

XX P1 Wei Y, Kroider BL, Rosen CA;

XX WP1: 2002 299258/29.

XX N-PSDR: AAD31065.

XX PT New isolated chemokine beta-15 polypeptide, useful for mediating

XX PT colony formation of bone marrow progenitor cells, mediating early

XX PT thymocyte proliferation and differentiation and for treating leukemia

XX PT -

XX CC Claim 18; Fig 1; 30pp; English.

XX CC The invention relates to a member of the human chemokine CC protein

XX CC family. In particular the invention relates to isolated nucleic acid

XX CC molecules encoding chemokine beta-15 (CKbeta-15). CKbeta-15 DNA is

XX CC useful for diagnosing a disorder of the thymus in an individual.

XX CC CKbeta-15 is useful for treating or inhibiting, in need of enhanced level

XX CC of chemokine beta-15 activity, cytotoxic activity, modulate activities

XX CC of cells in thymus preferably early thymocytes, mediate differentiation

XX CC of immature T-cell precursors into mature T-lymphocytes within the thymus or by

XX CC the apoptosis of specific subsets of thymocytes within the thymus. It

XX CC directly inducing the differentiation of specific subset. It directs the

XX CC homing of immature lymphocyte precursor to thymus for proper maturation,

XX CC modulates colony formation of bone progenitor cells and modulates early

XX CC thymocyte proliferation and differentiation. It is also useful as

XX CC molecular weight markers in analytical techniques. CKbeta-15 is useful

XX CC for suppressing myeloid cell proliferation in an individual and for

XX CC treating leukemia. CKbeta 15 DNA is used in chromosome identification,

XX CC prognostic assays and in diagnostic assays for detecting CKbeta-15

XX CC protein expression and in vivo imaging technique. The present sequence is

00 human CD44 15 protein.
 01
 02
 03
 04
 05
 06
 07
 08
 09
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000

00
 01
 02
 03
 04
 05
 06
 07
 08
 09
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546

Search completed: May 7, 2003, 10:36:47
Job time : 37 secs

```

XX 20-OCT-2000 (first entry)
DE Murine secondary lymphoid chemokine (SLC).
DE
XX Secondary lymphoid chemokine; SLC; cancer;
XX hyperproliferative disorders; prostatic hyperplasia;
XX proliferative breast disease; proliferative retinopathy;
XX melanoma; breast cancer; cancer; metastases; suppression;
XX angiogenesis; tumorigenesis; inflammation; immune response;
XX chemotaxis; graft rejection; autoimmune disease; mouse.
XX
OS Mus musculus.
XX
EN W0200038706-A2.
XX
FO 06-JUL-2000.
XX
PP 28-DEC-1999; 99WD-0831096.
XX
PR 31-DEC-1998; 98US-0114498.
XX
PA (CHIR ) CHIRON CORP.
XX
PI Keting C, Xin H, Chan WPF, Kothakota S, Williams LT, Winter JA;
XX
DR WPI: 2000-465631/40.
XX
DR N-PSDB: AAA47496.
XX
PT Treating cancer or hyperproliferative disorder and modulating dendritic
PT cell function in a mammal involves administering secondary lymphoid
PT chemokine to the mammal
XX
PS Claim 12: Fig 2: 53pp: English.
XX
CC Secondary lymphoid chemokines (SLC's), variants, fragments, and the
CC polynucleotides encoding the chemokines, variants and fragments,
CC anti-SLC antibodies or ligands for the CCR7 receptor can be used to
CC modulate dendritic cell function in a mammal which results in a
CC decreased primary immune response. SLC can be used to treat cancer or
CC hyperproliferative disorders such as prostatic hyperplasia,
CC proliferative breast diseases, proliferative retinopathy or pigmented
CC skin lesions. SLC is also useful for treating solid tumours such as
CC melanoma, breast cancer, tumours of the head and neck, cancers or
CC metastases of ovary, endometrium, urinary tract, stomach, testicle,
CC prostate, lung, bladder, pancreas, bone, liver, colon or rectum, or
CC metastases of unknown primary origin. SLC can also be used to
CC suppress angiogenesis particularly angiogenesis involved in cancer,
CC tumorigenesis, metastases and tumour growth, and for mediating
CC recruitment of leukocytes into sites of inflammation and immune
CC responses, particularly the chemokines of dendritic and other cells.
CC SLC is also useful in preventing graft rejection, prevention and
CC treatment of the autoimmune diseases and for enhancing an immune
CC response.
XX
SO Sequence 133 AA:
XX
Query Match 14.8%; Score 117.5; DB 21; Length 133;
Best Local Similarity: 29.7%; Pred No 5, 9e-06;
Matches 41; Conservative 22; Mismatch 52; Indels 23; Gaps 8;
QY 1 MNWIIAGLVAGPLGAWAPAVHTGQVFEDCLAV-HYFGWAVLKRAWITRTDEVSGSN 59
DB 10 LSLDLALCI-----PWTQG--SDGGGDDCLYSGKRIPYSIVR--GYRKOEPSLQCP 58
QY 60 LFAA:FLYLFNHRK-VCCNKRSEFYVGFAPRTIT-APHYVFAKIUNNGTFOAGPHAV 114
DB 59 IF-ALIFRNRHBSKFTDLCANTRDCWQNLNMRIRIQPAPRKGSTGCTKFNSTSRSG---- 113
QY 115 KRISGNSRTISSRFSNP 132
DB 114 -KKGGSKGCKRLEQTOP 130

```



,

Yeast 10, 653-657, 1994
 A>Title: April, a yeast gene encoding a putative permease for basic amino acids
 A:Reference number: S44329; MIMD:95029162; PMID:7941718
 A:Accession: S44329
 A:Molecule type: DNA
 A:Residues: 1-5170; 52-125; 126-127; 128-129; 130-131; 132-133; 134-135; 136-137; 138-139; 140-141; 142-143; 144-145; 146-147; 148-149; 150-151; 152-153; 154-155; 156-157; 158-159; 160-161; 162-163; 164-165; 166-167; 168-169; 170-171; 172-173; 174-175; 176-177; 178-179; 180-181; 182-183; 184-185; 186-187; 188-189; 190-191; 192-193; 194-195; 196-197; 198-199; 200-201; 202-203; 204-205; 206-207; 208-209; 210-211; 212-213; 214-215; 216-217; 218-219; 220-221; 222-223; 224-225; 226-227; 228-229; 230-231; 232-233; 234-235; 236-237; 238-239; 240-241; 242-243; 244-245; 246-247; 248-249; 250-251; 252-253; 254-255; 256-257; 258-259; 260-261; 262-263; 264-265; 266-267; 268-269; 270-271; 272-273; 274-275; 276-277; 278-279; 280-281; 282-283; 284-285; 286-287; 288-289; 290-291; 292-293; 294-295; 296-297; 298-299; 300-301; 302-303; 304-305; 306-307; 308-309; 310-311; 312-313; 314-315; 316-317; 318-319; 320-321; 322-323; 324-325; 326-327; 328-329; 330-331; 332-333; 334-335; 336-337; 338-339; 340-341; 342-343; 344-345; 346-347; 348-349; 350-351; 352-353; 354-355; 356-357; 358-359; 360-361; 362-363; 364-365; 366-367; 368-369; 370-371; 372-373; 374-375; 376-377; 378-379; 380-381; 382-383; 384-385; 386-387; 388-389; 390-391; 392-393; 394-395; 396-397; 398-399; 400-401; 402-403; 404-405; 406-407; 408-409; 410-411; 412-413; 414-415; 416-417; 418-419; 420-421; 422-423; 424-425; 426-427; 428-429; 430-431; 432-433; 434-435; 436-437; 438-439; 440-441; 442-443; 444-445; 446-447; 448-449; 450-451; 452-453; 454-455; 456-457; 458-459; 460-461; 462-463; 464-465; 466-467; 468-469; 470-471; 472-473; 474-475; 476-477; 478-479; 480-481; 482-483; 484-485; 486-487; 488-489; 490-491; 492-493; 494-495; 496-497; 498-499; 500-501; 502-503; 504-505; 506-507; 508-509; 510-511; 512-513; 514-515; 516-517; 518-519; 520-521; 522-523; 524-525; 526-527; 528-529; 530-531; 532-533; 534-535; 536-537; 538-539; 540-541; 542-543; 544-545; 546-547; 548-549; 550-551; 552-553; 554-555; 556-557; 558-559; 560-561; 562-563; 564-565; 566-567; 568-569; 570-571; 572-573; 574-575; 576-577; 578-579; 580-581; 582-583; 584-585; 586-587; 588-589; 590-591; 592-593; 594-595; 596-597; 598-599; 600-601; 602-603; 604-605; 606-607; 608-609; 610-611; 612-613; 614-615; 616-617; 618-619; 620-621; 622-623; 624-625; 626-627; 628-629; 630-631; 632-633; 634-635; 636-637; 638-639; 640-641; 642-643; 644-645; 646-647; 648-649; 650-651; 652-653; 654-655; 656-657; 658-659; 660-661; 662-663; 664-665; 666-667; 668-669; 670-671; 672-673; 674-675; 676-677; 678-679; 680-681; 682-683; 684-685; 686-687; 688-689; 690-691; 692-693; 694-695; 696-697; 698-699; 700-701; 702-703; 704-705; 706-707; 708-709; 710-711; 712-713; 714-715; 716-717; 718-719; 720-721; 722-723; 724-725; 726-727; 728-729; 730-731; 732-733; 734-735; 736-737; 738-739; 740-741; 742-743; 744-745; 746-747; 748-749; 750-751; 752-753; 754-755; 756-757; 758-759; 760-761; 762-763; 764-765; 766-767; 768-769; 770-771; 772-773; 774-775; 776-777; 778-779; 780-781; 782-783; 784-785; 786-787; 788-789; 790-791; 792-793; 794-795; 796-797; 798-799; 800-801; 802-803; 804-805; 806-807; 808-809; 810-811; 812-813; 814-815; 816-817; 818-819; 820-821; 822-823; 824-825; 826-827; 828-829; 830-831; 832-833; 834-835; 836-837; 838-839; 840-841; 842-843; 844-845; 846-847; 848-849; 850-851; 852-853; 854-855; 856-857; 858-859; 860-861; 862-863; 864-865; 866-867; 868-869; 870-871; 872-873; 874-875; 876-877; 878-879; 880-881; 882-883; 884-885; 886-887; 888-889; 890-891; 892-893; 894-895; 896-897; 898-899; 900-901; 902-903; 904-905; 906-907; 908-909; 910-911; 912-913; 914-915; 916-917; 918-919; 920-921; 922-923; 924-925; 926-927; 928-929; 930-931; 932-933; 934-935; 936-937; 938-939; 940-941; 942-943; 944-945; 946-947; 948-949; 950-951; 952-953; 954-955; 956-957; 958-959; 960-961; 962-963; 964-965; 966-967; 968-969; 970-971; 972-973; 974-975; 976-977; 978-979; 980-981; 982-983; 984-985; 986-987; 988-989; 990-991; 992-993; 994-995; 996-997; 998-999; 1000-1001; 1002-1003; 1004-1005; 1006-1007; 1008-1009; 1010-1011; 1012-1013; 1014-1015; 1016-1017; 1018-1019; 1020-1021; 1022-1023; 1024-1025; 1026-1027; 1028-1029; 1030-1031; 1032-1033; 1034-1035; 1036-1037; 1038-1039; 1040-1041; 1042-1043; 1044-1045; 1046-1047; 1048-1049; 1050-1051; 1052-1053; 1054-1055; 1056-1057; 1058-1059; 1060-1061; 1062-1063; 1064-1065; 1066-1067; 1068-1069; 1070-1071; 1072-1073; 1074-1075; 1076-1077; 1078-1079; 1080-1081; 1082-1083; 1084-1085; 1086-1087; 1088-1089; 1090-1091; 1092-1093; 1094-1095; 1096-1097; 1098-1099; 1100-1101; 1102-1103; 1104-1105; 1106-1107; 1108-1109; 1110-1111; 1112-1113; 1114-1115; 1116-1117; 1118-1119; 1120-1121; 1122-1123; 1124-1125; 1126-1127; 1128-1129; 1130-1131; 1132-1133; 1134-1135; 1136-1137; 1138-1139; 1140-1141; 1142-1143; 1144-1145; 1146-1147; 1148-1149; 1150-1151; 1152-1153; 1154-1155; 1156-1157; 1158-1159; 1160-1161; 1162-1163; 1164-1165; 1166-1167; 1168-1169; 1170-1171; 1172-1173; 1174-1175; 1176-1177; 1178-1179; 1180-1181; 1182-1183; 1184-1185; 1186-1187; 1188-1189; 1190-1191; 1192-1193; 1194-1195; 1196-1197; 1198-1199; 1200-1201; 1202-1203; 1204-1205; 1206-1207; 1208-1209; 1210-1211; 1212-1213; 1214-1215; 1216-1217; 1218-1219; 1220-1221; 1222-1223; 1224-1225; 1226-1227; 1228-1229; 1230-1231; 1232-1233; 1234-1235; 1236-1237; 1238-1239; 1240-1241; 1242-1243; 1244-1245; 1246-1247; 1248-1249; 1250-1251; 1252-1253; 1254-1255; 1256-1257; 1258-1259; 1260-1261; 1262-1263; 1264-1265; 1266-1267; 1268-1269; 1270-1271; 1272-1273; 1274-1275; 1276-1277; 1278-1279; 1280-1281; 1282-1283; 1284-1285; 1286-1287; 1288-1289; 1290-1291; 1292-1293; 1294-1295; 1296-1297; 1298-1299; 1300-1301; 1302-1303; 1304-1305; 1306-1307; 1308-1309; 1310-1311; 1312-1313; 1314-1315; 1316-1317; 1318-1319; 1320-1321; 1322-1323; 1324-1325; 1326-1327; 1328-1329; 1330-1331; 1332-1333; 1334-1335; 1336-1337; 1338-1339; 1340-1341; 1342-1343; 1344-1345; 1346-1347; 1348-1349; 1350-1351; 1352-1353; 1354-1355; 1356-1357; 1358-1359; 1360-1361; 1362-1363; 1364-1365; 1366-1367; 1368-1369; 1370-1371; 1372-1373; 1374-1375; 1376-1377; 1378-1379; 1380-1381; 1382-1383; 1384-1385; 1386-1387; 1388-1389; 1390-1391; 1392-1393; 1394-1395; 1396-1397; 1398-1399; 1400-1401; 1402-1403; 1404-1405; 1406-1407; 1408-1409; 1410-1411; 1412-1413; 1414-1415; 1416-1417; 1418-1419; 1420-1421; 1422-1423; 1424-1425; 1426-1427; 1428-1429; 1430-1431; 1432-1433; 1434-1435; 1436-1437; 1438-1439; 1440-1441; 1442-1443; 1444-1445; 1446-1447; 1448-1449; 1450-1451; 1452-1453; 1454-1455; 1456-1457; 1458-1459; 1460-1461; 1462-1463; 1464-1465; 1466-1467; 1468-1469; 1470-1471; 1472-1473; 1474-1475; 1476-1477; 1478-1479; 1480-1481; 1482-1483; 1484-1485; 1486-1487; 1488-1489; 1490-1491; 1492-1493; 1494-1495; 1496-1497; 1498-1499; 1500-1501; 1502-1503; 1504-1505; 1506-1507; 1508-1509; 1510-1511; 1512-1513; 1514-1515; 1516-1517; 1518-1519; 1520-1521; 1522-1523; 1524-1525; 1526-1527; 1528-1529; 1530-1531; 1532-1533; 1534-1535; 1536-1537; 1538-1539; 1540-1541; 1542-1543; 1544-1545; 1546-1547; 1548-1549; 1550-1551; 1552-1553; 1554-1555; 1556-1557; 1558-1559; 1560-1561; 1562-1563; 1564-1565; 1566-1567; 1568-1569; 1570-1571; 1572-1573; 1574-1575; 1576-1577; 1578-1579; 1580-1581; 1582-1583; 1584-1585; 1586-1587; 1588-1589; 1590-1591; 1592-1593; 1594-1595; 1596-1597; 1598-1599; 1600-1601; 1602-1603; 1604-1605; 1606-1607; 1608-1609; 1610-1611; 1612-1613; 1614-1615; 1616-1617; 1618-1619; 1620-1621; 1622-1623; 1624-1625; 1626-1627; 1628-1629; 1630-1631; 1632-1633; 1634-1635; 1636-1637; 1638-1639; 1640-1641; 1642-1643; 1644-1645; 1646-1647; 1648-1649; 1650-1651; 1652-1653; 1654-1655; 1656-1657; 1658-1659; 1660-1661; 1662-1663; 1664-1665; 1666-1667; 1668-1669; 1670-1671; 1672-1673; 1674-1675; 1676-1677; 1678-1679; 1680-1681; 1682-1683; 1684-1685; 1686-1687; 1688-1689; 1690-1691; 1692-1693; 1694-1695; 1696-1697; 1698-1699; 1700-1701; 1702-1703; 1704-1705; 1706-1707; 1708-1709; 1710-1711; 1712-1713; 1714-1715; 1716-1717; 1718-1719; 1720-1721; 1722-1723; 1724-1725; 1726-1727; 1728-1729; 1730-1731; 1732-1733; 1734-1735; 1736-1737; 1738-1739; 1740-1741; 1742-1743; 1744-1745; 1746-1747; 1748-1749; 1750-1751; 1752-1753; 1754-1755; 1756-1757; 1758-1759; 1760-1761; 1762-1763; 1764-1765; 1766-1767; 1768-1769; 1770-1771; 1772-1773; 1774-1775; 1776-1777; 1778-1779; 1780-1781; 1782-1783; 1784-1785; 1786-1787; 1788-1789; 1790-1791; 1792-1793; 1794-1795; 1796-1797; 1798-1799; 1800-1801; 1802-1803; 1804-1805; 1806-1807; 1808-1809; 1810-1811; 1812-1813; 1814-1815; 1816-1817; 1818-1819; 1820-1821; 1822-1823; 1824-1825; 1826-1827; 1828-1829; 1830-1831; 1832-1833; 1834-1835; 1836-1837; 1838-1839; 1840-1841; 1842-1843; 1844-1845; 1846-1847; 1848-1849; 1850-1851; 1852-1853; 1854-1855; 1856-1857; 1858-1859; 1860-1861; 1862-1863; 1864-1865; 1866-1867; 1868-1869; 1870-1871; 1872-1873; 1874-1875; 1876-1877; 1878-1879; 1880-1881; 1882-1883; 1884-1885; 1886-1887; 1888-1889; 1890-1891; 1892-1893; 1894-1895; 1896-1897; 1898-1899; 1900-1901; 1902-1903; 1904-1905; 1906-1907; 1908-1909; 1910-1911; 1912-1913; 1914-1915; 1916-1917; 1918-1919; 1920-1921; 1922-1923; 1924-1925; 1926-1927; 1928-1929; 1930-1931; 1932-1933; 1934-1935; 1936-1937; 1938-1939; 1940-1941; 1942-1943; 1944-1945; 1946-1947; 1948-1949; 1950-1951; 1952-1953; 1954-1955; 1956-1957; 1958-1959; 1960-1961; 1962-1963; 1964-1965; 1966-1967; 1968-1969; 1970-1971; 1972-1973; 1974-1975; 1976-1977; 1978-1979; 1980-1981; 1982-1983; 1984-1985; 1986-1987; 1988-1989; 1990-1991; 1992-1993; 1994-1995; 1996-1997; 1998-1999; 2000-2001; 2002-2003; 2004-2005; 2006-2007; 2008-2009; 2010-2011; 2012-2013; 2014-2015; 2016-2017; 2018-2019; 2020-2021; 2022-2023; 2024-2025; 2026-2027; 2028-2029; 2030-2031; 2032-2033; 2034-2035; 2036-2037; 2038-2039; 2040-2041; 2042-2043; 2044-2045; 2046-2047; 2048-2049; 2050-2051; 2052-2053; 2054-2055; 2056-2057; 2058-2059; 2060-2061; 2062-2063; 2064-2065; 2066-2067; 2068-2069; 2070-2071; 2072-2073; 2074-2075; 2076-2077; 2078-2079; 2080-2081; 2082-2083; 2084-2085; 2086-2087; 2088-2089; 2090-2091; 2092-2093; 2094-2095; 2096-2097; 2098-2099; 2100-2101; 2102-2103; 2104-2105; 2106-2107; 2108-2109; 2110-2111; 2112-2113; 2114-2115; 2116-2117; 2118-2119; 2120-2121; 2122-2123; 2124-2125; 2126-2127; 2128-2129; 2130-2131; 2132-2133; 2134-2135; 2136-2137; 2138-2139; 2140-2141; 2142-2143; 2144-2145; 2146-2147; 2148-2149; 2150-2151; 2152-2153; 2154-2155; 2156-2157; 2158-2159; 2160-2161; 2162-2163; 2164-2165; 2166-2167; 2168-2169; 2170-2171; 2172-2173; 2174-2175; 2176-2177; 2178-2179; 2180-2181; 2182-2183; 2184-2185; 2186-2187; 2188-2189; 2190-2191; 2192-2193; 2194-2195; 2196-2197; 2198-2199; 2200-2201; 2202-2203; 2204-2205; 2206-2207; 2208-2209; 2210-2211; 2212-2213; 2214-2215; 2216-2217; 2218-2219; 2220-2221; 2222-2223; 2224-2225; 2226-2227; 2228-2229; 2230-2231; 2232-2233; 2234-2235; 2236-2237; 2238-2239; 2240-2241; 2242-2243; 2244-2245; 2246-2247; 2248-2249; 2250-2251; 2252-2253; 2254-2255; 2256-2257; 2258-2259; 2260-2261; 2262-2263; 2264-2265; 2266-2267; 2268-2269; 2270-2271; 2272-2273; 2274-2275; 2276-2277; 2278-2279; 2280-2281; 2282-2283; 2284-2285; 2286-2287; 2288-2289; 2290-2291; 2292-2293; 2294-2295; 2296-2297; 2298-2299; 2300-2301; 2302-2303; 2304-2305; 2306-2307; 2308-2309; 2310-2311; 2312-2313; 2314-2315; 2316-2317; 2318-2319; 2320-2321; 2322-2323; 2324-2325; 2326-2327; 2328-2329; 2330-2331; 2332-2333; 2334-2335; 2336-2337; 2338-2339; 2340-2341; 2342-2343; 2344-2345; 2346-2347; 2348-2349; 2350-2351; 2352-2353; 2354-2355; 2356-2357; 2358-2359; 2360-2361; 2362-2363; 2364-2365; 2366-2367; 2368-2369; 2370-2371; 2372-2373; 2374-2375; 2376-2377; 2378-2379; 2380-2381; 2382-2383; 2384-2385; 2386-2387; 2388-2389; 2390-2391; 2392-2393; 2394-2395; 2396-2397; 2398-2399; 2400-2401; 2402-2403; 2404-2405; 2406-2407; 2408-2409; 2410-2411; 2412-2413; 2414-2415; 2416-2417; 2418-2419; 2420-2421; 2422-2423; 2424-2425; 2426-2427; 2428-2429; 2430-2431; 2432-2433; 2434-2435; 2436-2437; 2438-2439; 2440-2441; 2442-2443; 2444-2445; 2446-2447; 2448-2449; 2450-2451; 2452-2453; 2454-2455; 2456-2457; 2458-2459; 2460-2461; 2462-2463; 2464-2465; 2466-2467; 2468-2469; 2470-2471; 2472-2473; 2474-2475; 2476-2477; 2478-2479; 2480-2481; 2482-2483

A: Molibdolo Type: mRNA

Accession: U1061 - M12

Accession references: EMBL:Z22525

Organism family: postrivatus genome polypeptide

Keywords: silyproteolide polypeptide

Query Match 9482 Score 752 Id 22 Length 1171

Post Local ID 24,286 Prod. No. 292

Match 472 Conserved 181 Mismatches 672 Indels 262 Gaps 52

Q7 15 GAMA PAVHGVVFETIA YHPTWAVIBRAMITRQVSGSTN 59

16 878 GMDH VKHGVVFETIA PAVHGVVFETIA YHPTWAVIBRAMITRQVSGSTN 941

Q7 66 11AATFYHRRPHSVYDND 7SEVYKAPMLLAFPRVAKLHDSGCTCAHBAVKEL 117

18 942 PAVHGVVFETIA PAVHGVVFETIA YHPTWAVIBRAMITRQVSGSTN 983

Q7 118 GMDHVKHGVVFETIA PAVHGVVFETIA YHPTWAVIBRAMITRQVSGSTN 145

19 994 11AATFYHRRPHSVYDND 7SEVYKAPMLLAFPRVAKLHDSGCTCAHBAVKEL 117

Search completed: May 7, 2003, 10:19:02

Web Time: 0:20:00

RESULT 2

US-09-844-799A-20

Sequence 20, Application US/09/844-799A

Patent No. US2002/007610A1

GENERAL INFORMATION

APPLICANT: Laido, Yoshio

APPLICANT: Laido, Yoshio

TITLE OF INVENTION: Detection and Treatment of Breast Cancer

FILE REFERENCE: 600/211,000

CURRENT APPLICATION NUMBER: US/09/844-799A

CURRENT FILING DATE: 2001-04-12

PRIOR APPLICATION NUMBER: 09/146,500

PRIOR FILING DATE: 1998-09-04

PRIOR APPLICATION NUMBER: 06/271,877

PRIOR FILING DATE: 1998-01-20

PRIOR APPLICATION NUMBER: 06/209,155

PRIOR FILING DATE: 1998-07-09

NUMBER OF SEQ ID NOS: 45

SOFTWARE: Patent to version 4.0

SEQ ID NO: 20

LENGTH: 150

TYPE: PRT

ORGANISM: Homo sapiens

US-09-844-799A-20

Query Match: 100.0% Score: 790; DR: 100; Length: 150;

Best Local Similarity: 100.0% Prod. No. 1,90-790

Matches: 149; Conserved: 0; Mismatches: 0; Indels: 0; Gaps: 0;

US-10-000-759A-9

Sequence 9, Application US/10/000-759A

Patent No. US2002/014190A1

GENERAL INFORMATION

APPLICANT: Andrew, David P.

APPLICANT: Zabol, Brian A.

APPLICANT: Zabol, Brian A.

TITLE OF INVENTION: ANTIGEN-9-6 ANTIBODIES AND METHODS OF

FILE REFERENCE: 1855,1064-003

CURRENT APPLICATION NUMBER: US/09/844-799A

CURRENT FILING DATE: 2001-10-23

PRIOR APPLICATION NUMBER: US/09/844-799A

PRIOR FILING DATE: 2000-05-10

PRIOR APPLICATION NUMBER: US/09/844-799A

PRIOR FILING DATE: 1999-03-11

NUMBER OF SEQ ID NOS: 15

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO: 9

LENGTH: 150

TYPE: PRT

ORGANISM: Homo Sapiens

FEATURES:

NAME: E.C. Var (104)

LOCATION: (104) ... (104)

OTHER INFORMATION: Xaa Met or Thr

US-10-000-759A-9

Query Match: 99.2% Score: 790; DR: 120; Length: 150;

Best Local Similarity: 99.0% Prod. No. 6,90-790

Matches: 149; Conserved: 1; Mismatches: 1; Indels: 0; Gaps: 0;

US-09-777-25

Sequence 25, Application US/09/777-25

Patent No. US2002/009124A1

GENERAL INFORMATION

APPLICANT: Laido, Yoshio

APPLICANT: Laido, Yoshio

APPLICANT: Laido, Yoshio

TITLE OF INVENTION: ANTIGEN-9-6 ANTIBODIES AND METHODS OF

FILE REFERENCE: 1855,1064-003

CURRENT APPLICATION NUMBER: US/09/844-799A

CURRENT FILING DATE: 2001-10-23

PRIOR APPLICATION NUMBER: US/09/844-799A

PRIOR FILING DATE: 2000-05-10

PRIOR APPLICATION NUMBER: US/09/844-799A

PRIOR FILING DATE: 1999-03-11

NUMBER OF SEQ ID NOS: 15

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO: 9

LENGTH: 150

TYPE: PRT

ORGANISM: Homo Sapiens

FEATURES:

NAME: E.C. Var (104)

LOCATION: (104) ... (104)

OTHER INFORMATION: Xaa Met or Thr

US-10-000-759A-9

Query Match: 99.2% Score: 790; DR: 120; Length: 150;

Best Local Similarity: 99.0% Prod. No. 6,90-790

Matches: 149; Conserved: 1; Mismatches: 1; Indels: 0; Gaps: 0;

CORRESPONDENCE ADDRESS:
 ADDRESSEE: INYTE PHARMACEUTICALS, INC.
 STREET: 3174 PORTER DRIVE
 CITY: PALO ALTO
 STATE: CALIFORNIA
 COUNTRY: USA
 ZIP: 94304

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS-DOS
 SOFTWARE: Word Perfect 6.1 for Windows/MS Dos 6.2

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US-09/779,777
 FILING DATE: 06-Mar-2001
 CLASSIFICATION: <unknown>
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US-09/002,485
 FILING DATE: <unknown>

ATTORNEY/AGENT INFORMATION:
 NAME: BILLINGS, LOCY J.
 REGISTRATION NUMBER: 36,749
 REFERENCE/DOCKET NUMBER: FI 0459 03
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (650) 855-0555
 TELEFAX: (650) 845-4166

SEQUENCE CHARACTERISTICS:
 INFORMATION FOR SEQ ID NO: 25:
 LENGTH: 150 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear

IMMEDIATE SOURCE:
 LIBRARY: COLNCGT19
 CLONE: 1634813

SEQUENCE DESCRIPTION: SEQ ID NO: 25:
 US-09-799-777-25

Query Match 97.6%; Score 777; DB 10; Length 150;
 Best Local Similarity 96.0%; Freq. No. 1, de-77;
 Matches 147; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 MNMLTACTVAGFLGMAPAVHLCVFEVPCVLAHYPIGMAVTPRATYRQFVSQSL 60
 DB 1 MNMLTACTVAGFLGMAPAVHLCVFEVPCVLAHYPIGMAVTPRATYRQFVSQSL 60

QY 61 FAATLYLKHREHVCQHKSEHVSAMKIDARVAVATIRHRTVTCVPAVVRPSSG 120
 DB 61 FAATLYLKHREHVCQHKSEHVSAMKIDARVAVATIRHRTVTCVPAVVRPSSG 120

QY 121 NSRLSSKSTSNTESEKAGVSLTANSG 150
 DB 121 NSRLSSKSTSNTESEKAGVSLTANSG 150

QY 121 NSRLSSKSTSNTESEKAGVSLTANSG 150
 DB 121 NSRLSSKSTSNTESEKAGVSLTANSG 150

RESULT 6
 US-10-263-766-2
 Sequence 2, Application US/10263766
 Publication No. US20030073196A1
 GENERAL INFORMATION:
 APPLICANT: WEI, YING-FEI
 KREIDER, BRENT
 ROSEN, CRAIG
 TITLE OF INVENTION: CHEMOKINE BETA 15
 NUMBER OF SEQUENCES: 9
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: STEER, KESLER, GORDSTEN & FOX P.L.L.C.
 STREET: 1100 NEW YORK AVENUE, SUITE 600
 CITY: WASHINGTON
 STATE: D.C.
 COUNTRY: US
 ZIP: 20005-4944
 COMPUTER READABLE FORM.

MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/10-263-766
 FILING DATE: 04-Oct-2002
 CLASSIFICATION: <unknown>

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US-09/074,460
 FILING DATE: <unknown>
 APPLICATION NUMBER: 60/019,937
 FILING DATE: 17-JUN-1996

ATTORNEY/AGENT INFORMATION:
 NAME: Steer, Eric K.
 REGISTRATION NUMBER: 36,688
 REFERENCE/DOCKET NUMBER: 1489,0420001
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 202-371-2600
 TELEFAX: 202-371-2540

SEQUENCE CHARACTERISTICS:
 INFORMATION FOR SEQ ID NO: 2:
 LENGTH: 149 amino acids
 TYPE: amino acid
 TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 2:
 US-10-263-766-2

Query Match 97.4%; Score 775.5; DB 9; Length 149;
 Best Local Similarity 96.7%; Freq. No. 2, de-77;
 Matches 148; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 1 MNMLTACTVAGFLGMAPAVHLCVFEVPCVLAHYPIGMAVTPRATYRQFVSQSL 60
 DB 1 MNMLTACTVAGFLGMAPAVHLCVFEVPCVLAHYPIGMAVTPRATYRQFVSQSL 60

QY 61 FAATLYLKHREHVCQHKSEHVSAMKIDARVAVATIRHRTVTCVPAVVRPSSG 120
 DB 61 FAATLYLKHREHVCQHKSEHVSAMKIDARVAVATIRHRTVTCVPAVVRPSSG 119

QY 121 NSRLSSKSTSNTESEKAGVSLTANSG 150
 DB 120 NSRLSSKSTSNTESEKAGVSLTANSG 146

RESULT 7
 US-09-272-162-2
 Sequence 2, Application US/09272162
 Patent No. US20020019033A1
 GENERAL INFORMATION:
 APPLICANT: WEI, YING-FEI
 KREIDER, BRENT
 ROSEN, CRAIG
 TITLE OF INVENTION: CHEMOKINE BETA 15
 NUMBER OF SEQUENCES: 9
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: STEER, KESLER, GORDSTEN & FOX P.L.L.C.
 STREET: 1100 NEW YORK AVENUE, SUITE 600
 CITY: WASHINGTON
 STATE: D.C.
 COUNTRY: US
 ZIP: 20005-4944
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US-09-272-162
 FILING DATE: 19-Mar-1999
 CLASSIFICATION: <unknown>
 PRIOR APPLICATION DATA:

Wed May 7 14:15:59 2003

ms-10-039-659-4 - ramb

Page 7

1	PRIOR FILING DATE:	1997-10-17
2	PRIOR APPLICATION NUMBER:	60/063287
3	PRIOR FILING DATE:	1997-10-17
4	PRIOR APPLICATION NUMBER:	60/0632814
5	PRIOR FILING DATE:	1997-10-24
6	PRIOR APPLICATION NUMBER:	60/062816
7	PRIOR FILING DATE:	1997-10-24
8	PRIOR APPLICATION NUMBER:	60/063045
9	PRIOR FILING DATE:	1997-10-24
10	PRIOR APPLICATION NUMBER:	60/063082
11	PRIOR FILING DATE:	1997-10-31
12	PRIOR APPLICATION NUMBER:	60/063127
13	PRIOR FILING DATE:	1997-10-24
14	PRIOR APPLICATION NUMBER:	60/063327
15	PRIOR FILING DATE:	1997-10-27
16	PRIOR APPLICATION NUMBER:	60/063329
17	PRIOR FILING DATE:	1997-10-27
18	PRIOR APPLICATION NUMBER:	60/063550
19	PRIOR FILING DATE:	1997-10-28
20	PRIOR APPLICATION NUMBER:	60/063561
21	PRIOR FILING DATE:	1997-10-28
22	PRIOR APPLICATION NUMBER:	60/063704
23	PRIOR FILING DATE:	1997-10-29
24	PRIOR APPLICATION NUMBER:	60/063733
25	PRIOR FILING DATE:	1997-10-29
26	PRIOR APPLICATION NUMBER:	60/063735
27	PRIOR FILING DATE:	1997-10-29
28	PRIOR APPLICATION NUMBER:	60/063738
29	PRIOR FILING DATE:	1997-10-29
30	PRIOR APPLICATION NUMBER:	60/063755
31	PRIOR FILING DATE:	1997-10-17
32	PRIOR APPLICATION NUMBER:	60/064248
33	PRIOR FILING DATE:	1997-11-03
34	PRIOR APPLICATION NUMBER:	60/064359
35	PRIOR FILING DATE:	1997-11-07
36	PRIOR APPLICATION NUMBER:	60/064516
37	PRIOR FILING DATE:	1997-11-12
38	PRIOR APPLICATION NUMBER:	60/064545
39	PRIOR FILING DATE:	1997-11-17
40	PRIOR APPLICATION NUMBER:	60/064764
41	PRIOR FILING DATE:	1997-11-21
42	PRIOR APPLICATION NUMBER:	60/064853
43	PRIOR FILING DATE:	1997-11-24
44	PRIOR APPLICATION NUMBER:	60/065511
45	PRIOR FILING DATE:	1997-11-24
46	PRIOR APPLICATION NUMBER:	60/065730
47	PRIOR FILING DATE:	1997-11-24
48	PRIOR APPLICATION NUMBER:	60/069212
49	PRIOR FILING DATE:	1997-12-11
50	PRIOR APPLICATION NUMBER:	60/069278
51	PRIOR FILING DATE:	1997-12-11
52	PRIOR APPLICATION NUMBER:	60/069334
53	PRIOR FILING DATE:	1997-12-11
54	PRIOR APPLICATION NUMBER:	60/069544
55	PRIOR FILING DATE:	1997-12-16
56	PRIOR APPLICATION NUMBER:	60/071320
57	PRIOR FILING DATE:	1998-01-23
58	PRIOR APPLICATION NUMBER:	60/073612
59	PRIOR FILING DATE:	1998-02-04
60	PRIOR APPLICATION NUMBER:	60/074096
61	PRIOR FILING DATE:	1998-02-06
62	PRIOR APPLICATION NUMBER:	60/074892
63	PRIOR FILING DATE:	1998-02-06
64	PRIOR APPLICATION NUMBER:	60/077791
65	PRIOR FILING DATE:	1998-03-12
66	PRIOR APPLICATION NUMBER:	60/078010
67	PRIOR FILING DATE:	1998-03-20
68	PRIOR APPLICATION NUMBER:	60/079294
69	PRIOR FILING DATE:	1998-03-25
70	PRIOR APPLICATION NUMBER:	60/079663
71	PRIOR FILING DATE:	1998-02-27
72	PRIOR APPLICATION NUMBER:	60/079728
73	PRIOR FILING DATE:	1998-03-27

1	PRIOR APPLICATION NUMBER: 60/080165
2	PRIOR FILING DATE: 1998-03-31
3	PRIOR APPLICATION NUMBER: 60/081203
4	PRIOR FILING DATE: 1998-04-09
5	PRIOR APPLICATION NUMBER: 60/081229
6	PRIOR FILING DATE: 1998-04-09
7	PRIOR APPLICATION NUMBER: 60/081695
8	PRIOR FILING DATE: 1998-04-14
9	PRIOR APPLICATION NUMBER: 60/081817
10	PRIOR FILING DATE: 1998-04-15
11	PRIOR APPLICATION NUMBER: 60/081818
12	PRIOR FILING DATE: 1998-04-15
13	PRIOR APPLICATION NUMBER: 60/082999
14	PRIOR FILING DATE: 1998-04-22
15	PRIOR APPLICATION NUMBER: 60/083222
16	PRIOR FILING DATE: 1998-04-28
17	PRIOR APPLICATION NUMBER: 60/083245
18	PRIOR FILING DATE: 1998-04-29
19	PRIOR APPLICATION NUMBER: 60/084600
20	PRIOR FILING DATE: 1998-05-07
21	PRIOR APPLICATION NUMBER: 60/084627
22	PRIOR FILING DATE: 1998-05-07
23	PRIOR APPLICATION NUMBER: 60/085149
24	PRIOR FILING DATE: 1998-05-12
25	PRIOR APPLICATION NUMBER: 60/085323
26	PRIOR FILING DATE: 1998-05-13
27	PRIOR APPLICATION NUMBER: 60/085388
28	PRIOR FILING DATE: 1998-05-13
29	PRIOR APPLICATION NUMBER: 60/085399
30	PRIOR FILING DATE: 1998-05-13
31	PRIOR APPLICATION NUMBER: 60/085579
32	PRIOR FILING DATE: 1998-05-15
33	PRIOR APPLICATION NUMBER: 60/085647
34	PRIOR FILING DATE: 1998-05-15
35	PRIOR APPLICATION NUMBER: 60/085704
36	PRIOR FILING DATE: 1998-05-15
37	PRIOR APPLICATION NUMBER: 60/086414
38	PRIOR FILING DATE: 1998-05-22
39	PRIOR APPLICATION NUMBER: 60/086430
40	PRIOR FILING DATE: 1998-05-22
41	PRIOR APPLICATION NUMBER: 60/087106
42	PRIOR FILING DATE: 1998-05-28
43	PRIOR APPLICATION NUMBER: 60/088026
44	PRIOR FILING DATE: 1998-06-04
45	PRIOR APPLICATION NUMBER: 60/088730
46	PRIOR FILING DATE: 1998-06-10
47	PRIOR APPLICATION NUMBER: 60/089271
48	PRIOR FILING DATE: 1998-06-10
49	PRIOR APPLICATION NUMBER: 60/088810
50	PRIOR FILING DATE: 1998-06-10
51	PRIOR APPLICATION NUMBER: 60/089258
52	PRIOR FILING DATE: 1998-06-11
53	PRIOR APPLICATION NUMBER: 60/089432
54	PRIOR FILING DATE: 1998-06-11
55	PRIOR APPLICATION NUMBER: 60/089599
56	PRIOR FILING DATE: 1998-06-17
57	PRIOR APPLICATION NUMBER: 60/089907
58	PRIOR FILING DATE: 1998-06-18
59	PRIOR APPLICATION NUMBER: 60/090349
60	PRIOR FILING DATE: 1998-06-23
61	PRIOR APPLICATION NUMBER: 60/090429
62	PRIOR FILING DATE: 1998-06-24
63	PRIOR APPLICATION NUMBER: 60/090445
64	PRIOR FILING DATE: 1998-06-24
65	PRIOR APPLICATION NUMBER: 60/090538
66	PRIOR FILING DATE: 1998-06-24
67	PRIOR APPLICATION NUMBER: 60/090803
68	PRIOR FILING DATE: 1998-06-26
69	PRIOR APPLICATION NUMBER: 60/091360



.

.

GenCore version 5.1.4 P5_4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using SW model

Run on: May 7, 2003, 10:36:09 ; Search time 15 seconds
(without alignments)
294,229 Million owl updates/sec

Title: US-10-039-659-4

Perfect score: 796
Sequence: 1 MNLMLACLVAGVLCAMATVA.....NPISSKPVNVLITANSL 150

Scoring table: BLOSUM62
Gapop 10.0 ; Gapext 0.5

Searched: 262574 seqs, 2942292 residues

Total number of hits satisfying chosen parameters. 262574

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Issued_Patents_AA*

- 1: /sequs_6_14_1994/70A_7008.pep.*
- 2: /sequs_6_14_1994/71A_7100.pep.*
- 3: /sequs_6_14_1994/71A_7100.pep.*
- 4: /sequs_6_14_1994/71A_7100.pep.*
- 5: /sequs_6_14_1994/71A_7100.pep.*
- 6: /sequs_6_14_1994/71A_7100.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	775.5	97.4	149	2	US-08-874-460-2
2	115	14.4	133	1	US-08-874-460-2
3	115	14.4	133	2	US-08-874-460-2
4	115	14.4	133	3	US-08-874-460-2
5	115	14.4	133	4	US-08-874-460-2
6	115	14.4	133	5	US-08-874-460-2
7	115	14.4	133	6	US-08-874-460-2
8	115	14.4	133	7	US-08-874-460-2
9	115	14.4	133	8	US-08-874-460-2
10	115	14.4	133	9	US-08-874-460-2
11	115	14.4	133	10	US-08-874-460-2
12	115	14.4	133	11	US-08-874-460-2
13	115	14.4	133	12	US-08-874-460-2
14	115	14.4	133	13	US-08-874-460-2
15	115	14.4	133	14	US-08-874-460-2
16	115	14.4	133	15	US-08-874-460-2
17	115	14.4	133	16	US-08-874-460-2
18	115	14.4	133	17	US-08-874-460-2
19	115	14.4	133	18	US-08-874-460-2
20	115	14.4	133	19	US-08-874-460-2
21	115	14.4	133	20	US-08-874-460-2
22	115	14.4	133	21	US-08-874-460-2
23	115	14.4	133	22	US-08-874-460-2
24	115	14.4	133	23	US-08-874-460-2
25	115	14.4	133	24	US-08-874-460-2
26	115	14.4	133	25	US-08-874-460-2
27	115	14.4	133	26	US-08-874-460-2

28	91.5	11.5	73	3	US-08-722-719-57	Sequence 57, Appl
29	91.5	11.5	73	4	US-09-334-951-26	Sequence 26, Appl
30	91.5	11.5	73	5	US-09-334-951-57	Sequence 57, Appl
31	91.5	11.5	75	2	US-08-722-719-55	Sequence 55, Appl
32	91.5	11.5	75	3	US-09-334-951-55	Sequence 55, Appl
33	91.5	11.5	76	3	US-08-722-719-54	Sequence 54, Appl
34	91.5	11.5	76	3	US-08-722-719-54	Sequence 54, Appl
35	91.5	11.5	76	3	US-08-722-719-54	Sequence 54, Appl
36	91.5	11.5	76	4	US-09-334-951-59	Sequence 59, Appl
37	91.5	11.5	76	4	US-09-334-951-59	Sequence 59, Appl
38	91.5	11.5	76	4	US-09-334-951-59	Sequence 59, Appl
39	91.5	11.5	77	3	US-08-722-719-22	Sequence 22, Appl
40	91.5	11.5	77	3	US-08-722-719-22	Sequence 22, Appl
41	91.5	11.5	77	4	US-09-044-856A-12	Sequence 12, Appl
42	91.5	11.5	77	4	US-09-044-856A-12	Sequence 12, Appl
43	91.5	11.5	77	4	US-09-334-951-22	Sequence 22, Appl
44	91.5	11.5	77	4	US-09-334-951-61	Sequence 61, Appl
45	91.5	11.5	78	3	US-08-722-719-62	Sequence 62, Appl

ALIGNMENTS

RESULT 1
US-08-874-460-2 Affiliation: us-08874460
Sequence 2, Affiliation: us-08874460
Patent No. 5981231
GENERAL INFORMATION:
APPLICANT: WEI, YING-FEI
APPLICANT: KREIDER, BRENT
APPLICANT: ROSEN, CRAIG
FILE OF INVENTION: CHL-ETIP 307A 15
NUMBER OF SEQUENCES: 9
ADDRESS: CHEN, HESTER, STEVENSON & FOX P.L.L.C.
SINGLE: 100 NEW YORK AVENUE, SUITE 600
CITY: WASHINGTON
STATE: D.C.
COUNTRY: US
ZIP: 20005-3934
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/874,460
CLASSIFICATION: 435
FILING DATE: HEREWITH
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 65/015,837
FILING DATE: 17-JUN-1996
ATTORNEY/AGENT INFORMATION:
NAME: Steffe, Eric K.
REGISTRATION NUMBER: 36,668
TELEPHONE: 202-271-2500
TELEFAX: 202-271-2540
TELECOMMUNICATION INFORMATION:
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 149 amino acids
TYPE: amino acid
topology: linear
Molecule type: protein
US-08-874-460-2
Query Match 97.4%; Score 775.5; DB 2; Length 149;
Best local similarity 98.7%; Pred. No. 9,26-90;
Matches 149; Consistency 1; Indels 1; Gaps 1;
1 MNLMLACLVAGVLCAMATVA.....NPISSKPVNVLITANSL 150

10 1 MIMLWATLVANFIDAVANVHTGVEFDVTLAVHTFQWALBRAMVYRLOFVSSTN 60
 07 61 LPAATFYLRKREK--TAT--GV-AADTAAAPVAVKJHSHBELLGAGI HATKREK-- 113
 10 61 LPAATFYLRKREK--TAT--GV-AADTAAAPVAVKJHSHBELLGAGI HATKREK-- 113
 07 115 KRLSSNPKLSSKRSNP 142
 10 115 KRLSSNPKLSSKRSNP 140

RESULT 2

US-08-514-014-6

Sequence 6, Application US/08514014

Patent No. 6707829

GENERAL INFORMATION:

APPLICANT: Jacobs, Kenneth

APPLICANT: McCoy, John

APPLICANT: Kolchak, Kerry

TITLE OF INVENTION: DNA SEQUENCES AND SECRETED PROTEINS

TITLE OF INVENTION: ENCODED THEREBY

NUMBER OF SEQUENCES: 12

CORRESPONDENCE ADDRESS:

ADDRESSEE: Genetics Institute, Inc. - Local Affairs

STREET: 87 Cambridgepark Drive

CITY: Cambridge

STATE: Massachusetts

COUNTRY: USA

ZIP: 02140

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM pc compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patcut to Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08514-014

FILING DATE:

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Brown, Scott A.

REGISTRATION NUMBER: 42,724

REFERENCE/DOCKET NUMBER: 616000

TELEPHONE: (617) 498-8224

TELEFAX: (617) 876-5891

INFORMATION FOR SEQ ID NO: 61

SEQUENCE CHARACTERISTICS:

LENGTH: 133 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: Protein

US-08-514-014-6

Query Match 14.4% Score 115; DB 1; Length 133

Best Local Similarity 41.2% Prod. No. 1,20-062

Matches 43; Conservative 20; Mismatches 57; Indels 18; Gaps 8

07 1 MIMLWATLVANFIDAVANVHTGVEFDVTLAVHTFQWALBRAMVYRLOFVSSTN 59

10 5 MIMLWATLVANFIDAVANVHTGVEFDVTLAVHTFQWALBRAMVYRLOFVSSTN 58

07 60 LPAATFYLRKREK--WGNKRSKPEVAVKELAP--APRVAALSHHROTVQAPRVA 114

10 60 LPAATFYLRKREK--WGNKRSKPEVAVKELAP--APRVAALSHHROTVQAPRVA 114

07 115 KRLSSNPKLSSKRSNP 142

10 115 KRLSSNPKLSSKRSNP 140

RESULT 4

US-08-843-823-6

Sequence 6, Application US/08843823

Patent No. 5969094

GENERAL INFORMATION:

APPLICANT: Jacobs, Kenneth

APPLICANT: McCoy, John

APPLICANT: Kolchak, Kerry

TITLE OF INVENTION: DNA SEQUENCES AND SECRETED PROTEINS

TITLE OF INVENTION: ENCODED THEREBY

NUMBER OF SEQUENCES: 12

CORRESPONDENCE ADDRESS:

ADDRESSEE: Genetics Institute, Inc. - Local Affairs

STREET: 87 Cambridgepark Drive

CITY: Cambridge

STATE: Massachusetts

COUNTRY: USA

ZIP: 02140

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM pc compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patcut to Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08843-823

FILING DATE: 10-APR-1997

CLASSIFICATION: 540

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/514,014

FILING DATE: 11-AUG-1995

ATTORNEY/AGENT INFORMATION:

NAME: Brown, Scott A.

REGISTRATION NUMBER: 42,724

REFERENCE/DOCKET NUMBER: 616000

TELEPHONE: (617) 498-8224

TELEFAX: (617) 876-5891

INFORMATION FOR SEQ ID NO: 61

SEQUENCE CHARACTERISTICS:

LENGTH: 133 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: Protein

US-08-843-823-6

Query Match 14.4% Score 115; DB 2; Length 133

Best Local Similarity 41.2% Prod. No. 1,20-062

Matches 43; Conservative 20; Mismatches 57; Indels 18; Gaps 8

07 1 MIMLWATLVANFIDAVANVHTGVEFDVTLAVHTFQWALBRAMVYRLOFVSSTN 59

10 5 MIMLWATLVANFIDAVANVHTGVEFDVTLAVHTFQWALBRAMVYRLOFVSSTN 58

07 60 LPAATFYLRKREK--WGNKRSKPEVAVKELAP--APRVAALSHHROTVQAPRVA 114

10 60 LPAATFYLRKREK--WGNKRSKPEVAVKELAP--APRVAALSHHROTVQAPRVA 114

07 115 KRLSSNPKLSSKRSNP 142

10 115 KRLSSNPKLSSKRSNP 140

[illegible]

```

1 REGISTRATION NUMBER: 33,954
2 REFERENCE/ACCESS NUMBER: PI-0903 US
3 TELECOMMUNICATION INFORMATION:
4 TELEPHONE: 415-855-0555
5 TELEFAX: 415-852-0195
6 INFORMATION FOR SEQ. ID NO.: 2:
7 SEQUENCE CHARACTERISTICS:
8 LENGTH: 93 amino acids
9 TYPE: amino acid
10 STRANDEDNESS: single
11 TOPOLOGY: linear
12 MOLECULE TYPE: pepptide
13 IMMEDIATE SOURCE:
14 LIBRARY: Prostrate
15 CLONE: 836820
16 US-08-613-682-2

```

[illegible]

Sequence 2, Application US/08936772
Patent No. 6015883
GENERAL INFORMATION:
AFFILIANT: Hawkins, Phillip R.
APPLICANT: Bandman, Olga
APPLICANT: Murty, Lynn E.
TITLE OF INVENTION: NOVEL RANTIS HOMOLOG FROM PROSTATE
NUMBER OF SEQUENCES: 5
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: U.S.
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FASTSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICANT: MERRILL, G. G. 926,772
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/634,682
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Luthier, Barbara J
REGISTRATION NUMBER: 33,954
REFERENCE/DOCKET NUMBER: PR-0063 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-855-0555
TELEFAX: 415-852-0195
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 93 amino acids
TYPE: amino acid
STANDARD:35 single
TOPOLOGY: linear
MOLECULE TYPE: peptide
IMMEDIATE SOURCE:

REGISTRATION NUMBER: 36,698
 REGISTRATION NUMBER: 1404 042000
 TELECOMMUNICATION INFORMATION
 TELEPHONE: 202-371-2600
 TELEFAX: 202-371-2640
 INFORMATION FOR SEQ ID NO: 3:



GeneCore version 5.1.4.P5_4578
Copyright (c) 1993 - 2003 CompuGen Ltd.

100 protein - protein search, using SW model

Run on: May 7, 2003, 10:29:24 : Search time 12 seconds

(without alignments)
518,454 Million cell updates/sec

Title: US-10-039-659-4

Perfect score: 796

Sequence: 1 MRLHLAGVAVATIAAVAA...NLSSEKRVALLSANSGL 150

Scoring table: BL0SDM62

Gapop 10.0, Gapext 0.5

Searched: 11292 seqs, 1176228 residues

Total number of hits satisfying chosen parameters: 11292

Minimum DB seq length: 0

Maximum IP seq length: 20000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt40*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	796	100.0	150	SV25_HUMAN	015444 homo sapien
2	316	39.7	144	SV25_MOUSE	015903 mus muscu
3	115	14.4	133	SV21_MOUSE	009006 mus muscu
4	112	14.1	94	SV26_HUMAN	079258 homo sapien
5	107	13.4	122	SV06_MOUSE	011670 mus muscu
6	103.5	13.0	134	SV01_HUMAN	000045 homo sapien
7	102	12.8	127	SV28_HUMAN	000713 homo sapien
8	97	12.2	97	SV29_MOUSE	000069 mus muscu
9	96	12.1	120	SV27_MOUSE	002180 mus muscu
10	94	11.8	96	SV20_FAT	097884 rattus norv
11	93.5	11.7	119	SV24_HUMAN	000175 homo sapien
12	93	11.7	116	SV06_MOUSE	007784 mus muscu
13	91.5	11.5	120	SV23_HUMAN	052773 homo sapien
14	88.5	11.1	120	SV16_HUMAN	015467 h small ind
15	86.5	10.9	91	SV05_HUMAN	011099 homo sapien
16	85.5	10.7	92	SV04_MOUSE	011099 mus muscu
17	85	10.7	94	SV17_HUMAN	005092 homo sapien
18	84	10.6	130	SV29_MOUSE	009112 mus muscu
19	83.5	10.5	97	SV28_MOUSE	051671 homo sapien
20	83	10.4	114	SV01_FAT	051672 rattus norv
21	83	10.4	93	SV01_FAT	051672 rattus norv
22	81.5	10.3	112	SV15_HUMAN	010069 homo sapien
23	81	10.2	96	SV20_HUMAN	070556 homo sapien
24	80.5	10.1	92	SV05_FAT	002231 fati or m
25	79.5	10.0	91	SV05_MOUSE	002231 mus muscu
26	79	9.9	92	SV03_FAT	050023 rattus norv
27	78.5	9.9	114	SV01_MOUSE	047993 mus muscu
28	78.5	9.9	119	SV24_MOUSE	091800 mus muscu
29	78	9.8	149	SV29_MOUSE	011149 mus muscu
30	77.5	9.7	91	SV05_HUMAN	009157 kaposi's sa
31	77	9.6	94	SV12_KSHV	004019 h demoral b
32	76.5	9.5	89	SV18_HUMAN	052774 h small ind
33	75.5	9.5	89	SV18_HUMAN	052774 h small ind

44	75.5	9.5	98	SV19_HUMAN	099741 homo sapien
45	75.5	9.5	112	SV27_HUMAN	099741 homo sapien
46	75.5	9.5	395	SV01_MOUSE	045198 mus muscu
47	75	9.4	573	SV01_YEAST	048771 saccharomy
48	75	9.4	590	SV01_YEAST	048771 saccharomy
49	74.5	9.4	92	SV04_FAT1	044542 organocho
40	74	9.3	751	SV02_FAT1	091406 caecotriball
41	71	9.1	1134	SV02_MOUSE	091406 caecotriball
42	72.5	9.2	93	SV14_HUMAN	016627 homo sapien
43	73.5	9.2	188	SV19_MOUSE	023463 mus muscu
44	73	9.2	148	SV02_FAT	014844 rattus norv
45	73	9.2	611	SV01_YEAST	044542 organocho

ALIGNMENTS

RESULT 1

SV25_HUMAN

015444 928617 STANDARD PR1 150 AA.

15-JUL-1998 (Ref. 36, Created)

15-JUL-1998 (Ref. 36, Last sequence update)

15-JUN-2002 (Ref. 41, Last annotation update)

Small, inducible, soluble, A2, precursor (CH25) (chemokine TRK)

(thymus-expressed chemokine).

SV25 OR TRK.

homo sapiens (human).

Inkaryota: Metazoa: Chordata: Cephalata: Vertebrata: Euteleostomi:

Mammalia: Eutheria: Primates: Catarrhini: Hominoidea: Homo:

NCHI_Taxid=9606;

SEQUENCE FROM N.A. (ISOFORM 2).

TRKOR-Thymus:

MEDLINE 92429775, Pubmed 9285413;

Vicari A.P., Fianora D.J., Medlock J.A., Foster J.S., Singh K.P.,

Moren S., Copeland N.G., Gillett D.J., Jenkins N.A., Baron R.P.,

Zlotnik A.;

TRK: a novel or chemokine specifically expressed by thymic

dentritic cells and potentially involved in T cell development.;

Immunity 7:291-401(1997).

[2]

SEQUENCE FROM N.A. (ISOFORM 2).

TRKOR-Thymus:

Medlock J.A., Fianora D.J., Vicari A.P., Singh K.P.,

Moren S., Copeland N.G., Gillett D.J., Jenkins N.A., Baron R.P.,

Zlotnik A.;

TRK: a novel or chemokine specifically expressed by thymic

dentritic cells and potentially involved in T cell development.;

Immunity 7:291-401(1997).

[3]

RECEPTOR INTERACTION.

MEDLINE 92248119, Pubmed 10229797;

Edwards A., Gutierrez J., Virena V., Ardayn G., Marquez G.;

Identification of the orphan chemokine receptor GPR 96 as TRK, the

receptor for the chemokine TRK.;

J. Immunol. 162:6671-6675(1999).

FUNCTION: POTENTIALLY INVOLVED IN T CELL DEVELOPMENT, T CELL MIGRA-

TION AND CHEMOTACTIC ACTIVITY. IN THYMUS, MACROPHAGES, TREG-1

CELLS, AND B-1B-2 CELLS, BUT IS INACTIVE ON PERIPHERAL BLOOD

LYMPHOCYTES AND MONOCYTES. BINDS TO GPR96, ISOFORM 2 IN AN

ANTAGONISTIC MANNER.

SUBCELLULAR LOCATION: Secreted.

ADDITIONAL INFORMATION: 2-21 amino acids (26 aa) and 219-residue

are produced by alternative splicing.

1. secreted, 2. 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122,

123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136,

137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150,

151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164,

165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178,

179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192,

193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206,

207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220,

221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234,

235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248,

249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262,

263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276,

This SWISS-PROT entry is copyrighted. It is provided through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial

RA Sasaki H., Sato K., Schoenbach C., Soga T., Shibata Y., Storch K.-P.,
 RA Suzuki H., Togo-Oka K., Wang K.H., Wetz C., Whitaker C., Wilming L.,
 RA Wyszynski A., Yoshida K., Hasegawa Y., Kawaji H., Kohlsunk S.,
 RA Hayashizaki Y.,
 FT "Functional annotation of a full length mouse cDNA collection";
 RL Nature 409:685-690(2001);

RN
 RP SEQUENCE FROM N.A.
 RC TISSUE=THYMUS GLAND,
 RA Strausberg K.,

RL SubmitToJ (Apr-2002), the EMBL, Genbank/Trdb databases.
 DR EMBL: AJ242587, CAB5256.1,
 DR EMBL: AF124572, AA054522.1,
 DR EMBL: AF125571, AAD56601.1,
 DR EMBL: AK007663, BAB25171.1,
 DR EMBL: BC028505, AA028505.1,
 DR HSSP: Q98157, ICM9,
 DR M30: M311320030, Scy17,
 DR InterPro: IP0008277, G2-Chemokine_sml,
 DR InterPro: IP0018411, Chemokine_IL8,
 DR Pfam: PF00044, IL8, 1,
 DR SMART: SM00199, SCY, 1,
 DR ProSite: PS00472, SMALL_CITOKINES_00, 1,
 KW Signal.

FT CHAIN 1 20 THYMUS AND ACTIVATION-REGULATED
 FT SIGNAL 31 93 CHEMOKINE.
 FT SEQUENCE 93 AA; 1046 MW; 6EFC4FDEEE00CE CMC64;

Query Match 11.2%; Score 89.5; DB 11; Length 93;
 Best Local Similarity 28.3%; Pred. No. 0.043;
 Matches 25; Conservative 20; Mismatches 37; Indels 9; Gaps 4;

QY 1 MNMLACTVAGFLGAMAVAVHICQVEEDCLAVHYTGMAVLR--AMTYRIGPVSGSC 48
 Db 4 LQMLLAALLCTFQIQAARATVNGRECDLYRK--CAPIIKLVSW---YKISVRC 57
 QY 59 MTPAATVYLRKRRKRVGNSPEVCFAKLL 98
 Db 58 SPDAIVE-LIVGKLLICADPKRHRKALNV 88

RESULT 11

ID Q9R043 PRELIMINARY; PRT; 131 AA.
 AC Q9R043;
 DT 01-MAY-2000 (TREMBL) 13, Created;
 DT 01-MAY-2000 (TREMBL) 13, Last sequence update;
 DT 01-MAY-2002 (TREMBL) 20, Last annotation update;
 DE CC Chemokine ABCD-2.
 GN SCY17 OR ABCD-2.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
 OX NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=LIVER;
 RX MEDLINE=99438049; PubMed=10508268;
 RA Schaniel C., Salusto F., Ruedi C., Sideras P., Melchers F.,
 RA ROLLIN A.G.;

FT "Three chemokines with potential functions in T lymphocyte-independent
 FT and -dependent B lymphocyte stimulation";
 FT Eur. J. Immunol. 29:2921-2927(1999).
 RL EMBL: AF125570, AAD56601.1,
 DR HSSP: Q98157, ICM9,
 DR M30: M311320030, Scy17,
 DR InterPro: IP0008277, G2-Chemokine_sml,
 DR InterPro: IP0018411, Chemokine_IL8,
 DR Pfam: PF00044, IL8, 1,
 DR SMART: SM00199, SCY, 1,
 DR ProSite: PS00472, SMALL_CITOKINES_00, 1,
 DR PROSITE: PS00472, SMALL_CITOKINES_00, 1,
 RX MEDLINE=99113453; PubMed=9914924;

Query Match 11.2%; Score 89.5; DB 11; Length 131;
 Best Local Similarity 28.3%; Pred. No. 0.065;
 Matches 26; Conservative 20; Mismatches 37; Indels 9; Gaps 4;

QY 1 MNMLACTVAGFLGAMAVAVHICQVEEDCLAVHYTGMAVLR--AMTYRIGPVSGSC 58
 Db 42 LQMLLAALLCTFQIQAARATVNGRECDLYRK--CAPIIKLVSW---YKISVRC 95
 QY 59 MTPAATVYLRKRRKRVGNSPEVCFAKLL 90
 Db 58 SPDAIVE-LIVGKLLICADPKRHRKALNV 88

RESULT 12

ID Q9R043 PRELIMINARY; PRT; 89 AA.
 AC Q9R043;
 DT 01-MAY-2000 (TREMBL) 15, Created;
 DT 01-MAY-2000 (TREMBL) 15, Last sequence update;
 DT 01-DEC-2001 (TREMBL) 19, Last annotation update;
 DE CC Chemokine K203 precursor.
 GN K203.
 OS Gallus gallus (Chicken).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
 OX Gallus.
 OX NCBI_TaxID=9031;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC MEDLINE=20170441; PubMed=10704244;
 RA Sick C., Schneider K., Staeheli P., Welting K.C.;

FT "Novel chemokine C20 and CC Chemokines";
 FT Cytokine 12:181-186(2000).
 FT EMBL: Y18632, CAB75356.1,
 FT HSSP: P13236, IHOM.
 FT InterPro: IP001811, Chemokine_IL8,
 FT Pfam: PF00048, IL8, 1,
 FT SMART: SM00199, SCY, 1,
 KW Signal.
 FT CHAIN 1 21 POTENTIAL.
 FT SIGNAL 22 89 CHEMOKINE_K203.
 FT SEQUENCE 89 AA; 9896 MW; 6FA2EA7A4950CA75 CMC64;

Query Match 11.1%; Score 88; DB 13; Length 89;
 Best Local Similarity 30.5%; Pred. No. 0.059;
 Matches 29; Conservative 23; Mismatches 23; Indels 28; Gaps 3;

QY 5 MACTVAGFLGAMAVAVHICQVEEDCLAVHYTGMAVLR--AMTYRIGPVSGSC 53
 Db 7 VLALLASF-----GSKASAPVDPVPTCTTYTRKIPRNIGRHS 50
 QY 54 VSCSNLPAATVYLRKRRKRVGNSPEVCFAKLL 88
 Db 51 TSTSCSKPALIF--ITKREVCANPSUPWVQRILQ 84

RESULT 13

ID Q9PT54 PRELIMINARY; PRT; 100 AA.
 AC Q9PT54;
 DT 01-MAY-2000 (TREMBL) 13, Created;
 DT 01-MAY-2000 (TREMBL) 13, Last sequence update;
 DT 01-DEC-2001 (TREMBL) 19, Last annotation update;
 DE Chemokine CK-1.
 OS Oncorhynchus kisutch (Coho salmon).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;
 OC Proteobacteria; Salmoniformes; Salmonidae; Oncorhynchus.
 OX NCBI_TaxID=8019;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC MEDLINE=99113453; PubMed=9914924;

